Therapeutic strategies using VEGF inhibitors in colorectal cancer;Implications thérapeutiques des inhibiteurs du VEGF dans le cancer colorectal

Bulletin du Cancer

Volumn 92, Issue SPEC. ISS., 2005, Pages

  Boige, Valérie ^a   Malka, David ^a   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis; Antiangiogenic agent; Colorectal cancer; VEGF; VEGF inhibitor

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENIC FACTOR; APC PROTEIN; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; FLUOROURACIL; FOLINIC ACID; IMC IC 11; IRINOTECAN; OXALIPLATIN; PAZOPANIB; RAS PROTEIN; RIBOZYME; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTESTINE PERFORATION; LOW DRUG DOSE; NEOVASCULARIZATION (PATHOLOGY); NEUROTOXICITY; NONHUMAN; ONCOGENE RAS; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 30144441984     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-5.
2. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7.
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
7. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. A. Folfiri followed by Folfox6 or the reverse sequence in advanced colorectal cancer: a randomized Gercor study. J Clin Oncol 2004; 22: 229-37.
8. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
9. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 5: 10931-4.
10. Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst 1978; 61: 639-43.
11. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987 23; 235: 442-7.
12. Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 2005; 32: 61-8.
13. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
14. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-12.
15. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
16. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
17. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132: 541-6.
18. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998; 34: 337-40.
19. Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 3609-14.
20. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001; 61: 6050-4.
21. Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, et al. Cyclooxygenase 2- and prostaglandin E (2) receptor EP (2)-dependent angiogenesis in Ape (Delta716) mouse intestinal polyps. Cancer Res 2002; 62: 506-11.
22. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9.
23. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
24. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-97.
25. Gordon MS, Margolin K, Talpaz M, Sledge Jr. GW, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
26. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody tovascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19: 851-6.
27. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
29. Hurwitz H, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.J Clin Oncol 2005; 20: 3502-8.
30. Scappaticci F, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab. Proc Am Soc Clin Oncol Gastro Intest 2004 (abstract 235).
31. Koeppen HW, Ince WL, Holmgren E, et al. Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatatic colorectal cancer. 16th EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics. 2004.
32. Hedrick EE, Hurwitz H, Sarkar S, Griffing S, Novotny W, Grothey A. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 2004; 23: 249 (abstract 3517).
33. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Randolph Hecht J, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005 (sous presse).
34. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005 (sous presse).
35. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. High-dose bevacizumab improves survival when combined with Folfox4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2005; 23: 1s; (abstract 2).
36. Hochster HS, Welles L, Hart L, Ramanathan RK, Hainsworth J, Jirau-Lucca G, et al. Safety and efficacy of bevacizumab when added to oxaliplatin/ fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1 & 2 Studies. Proc Am Soc Clin Oncol 2005; 23: 249s (abstract 3515).
37. Chen H, Mooney M, Boron M, Grochow J, Zwiebel D, Vena, et al. Bevacizumab plus 5-FU/leucovorin for advanced colorectal cancer that progressed after standard chemotherapies: An NCI treatment referral center trial (TRC-0301). Proc Am Soc Clin Oncol 2004; 23: 249; (abstract 3515).
38. Saltz LB, Lenz H, Hochster H, Wadler S, Hoff P, Kemeny N, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 2005; 23: 248s (abstract 3508).
39. Saltz LB, Meropol NJ, Loehrer Sr. PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
40. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
41. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-89.
42. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60: 4819-24.
43. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005 (sous presse).
44. Morgan B, Thomas AL, Drevs J, Hennig J, Buchet M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-64.
45. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005; 16: 558-65.
46. Steward WP, Thomas A, Morgan B, Wiedenmann B, Barrel C, Vanhoefer U, et al. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with Folfox-4 as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: 259 (abstract 3556).
47. Schleucher N, Trarbach T, Junker U, Tewes M, Masson E, Lebwohl D, et al. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with Folfiri as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: 249 (abstract 3558).
48. Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (Confirm-1). Proc Am Soc Clin Oncol 2005; 23: 2s (abstract LBA3).
49. Venook A, Hurwitz H, Cunningham C, Burris HA, Aitchison R, Radka S, et al. Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme), in combination with chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 256 (abstract 1025).
50. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11.
51. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
52. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology 2002; 16(12 Suppl 14): 31-7.
53. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62: 5778-84.
54. Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2 derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 2004; 64: 279-85.
55. Kohne C, de Greve J, Bokemeyer C, Lang I, Vergauwe P, Braumann D, et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. Proc Am Soc Clin Oncol 2005; 23: 252s (abtract 3525).
56. Maiello E, Giuliani F, Romito S, Pezzella G, Mallamaci R, Di Renzo N, et al. Phase II randomized study of Folfiri vs Folfiri + Celecoxib in first line treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 2005; 23: 284s (abtract 3656).
57. Mitchell E, Marshall J, Chang J, Ganju V, Jeffery M, Schulz J, et al. Randomized phase III study of 3 irinotecan regimens in 1st-line metastatic colorectal cancer (CRC): safety/tolerability of irinotecan + oral capecitabine with or without celecoxib (BICC). Proc Am Soc Clin Oncol 2005; 23: 283s (abstract 3652).
58. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 26: 4082-5.
59. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced anti-angiogenic action is mediated by ceramide through depletion of VEGF receptors, and antagonized by sphingosine-1-phosphate. Blood 2005; 1 (sous presse).
60. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21: 4444-54.
61. Dal Lago L, Richter MF, Cancela AI, Fernandes SA, Jung KT, Rodrigues AC, et al. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs 2003; 21: 359-66.
62. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med 2004; 10: 145-7.
63. Bikfalvi A. Angiogenèse tumorale. Bull Cancer 2003; 90: 449-58.